{"title":"Research of affordability to essential medicines for coronary heart disease in Ukraine.","authors":"Natalia Bilousova, Natalia Tkachenko, Nataliia Kozhuharyova, Maryna Dolzhenko","doi":"10.1080/20523211.2025.2470841","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The issue of population access to medicines is relevant worldwide. Pandemics, natural disasters, wars negatively affect the population's access to medicines, as emphasised by the WHO and the UN.</p><p><strong>Methods: </strong>The analysis of scientific publications in the Ukrainian scientometric databases (NRAT, OUCI); Scopus, Web of Science, Pubmed, Medline, BMJ and Embase; the legal field for providing medical care to patients with CHD and comorbid conditions and its pharmaceutical component. The EML of Europe and Ukraine are compared; the clinical recommendations and pharmacotherapy of European/American Societies of Cardiology (ESC/AHA) and Ukrainian for patients with CHD and comorbid conditions are compared.</p><p><strong>Results: </strong>The prices of medicines that are not part of the 'Affordable Medicines' program and are included in the EML lists were analysed; their availability for Ukrainian patients in wartime conditions was determined. The legal field of providing medical care to patients with CHD and comorbid conditions has been formed. It was established that not all medicines specified in the EML are registered on the territory of Ukraine and included in the Program of Medical Guarantees (PMG).</p><p><strong>Conclusion: </strong>The PMG includes most of the EML medicines. The modern pharmacotherapy of CHD and comorbid conditions has a positive impact on the budget of the health care system in clinical practice proposed by the ESC/AHA was determined. The lists of medicines in the PMG in Ukraine, need to be revised on the basis of the Health Technology Assessment for further inclusion in the state program 'Affordable Medicines' for long-term use by patients with CHD and comorbid conditions. These measures will improve the quality of pharmaceutical care for these patients.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2470841"},"PeriodicalIF":3.3000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921159/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20523211.2025.2470841","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The issue of population access to medicines is relevant worldwide. Pandemics, natural disasters, wars negatively affect the population's access to medicines, as emphasised by the WHO and the UN.
Methods: The analysis of scientific publications in the Ukrainian scientometric databases (NRAT, OUCI); Scopus, Web of Science, Pubmed, Medline, BMJ and Embase; the legal field for providing medical care to patients with CHD and comorbid conditions and its pharmaceutical component. The EML of Europe and Ukraine are compared; the clinical recommendations and pharmacotherapy of European/American Societies of Cardiology (ESC/AHA) and Ukrainian for patients with CHD and comorbid conditions are compared.
Results: The prices of medicines that are not part of the 'Affordable Medicines' program and are included in the EML lists were analysed; their availability for Ukrainian patients in wartime conditions was determined. The legal field of providing medical care to patients with CHD and comorbid conditions has been formed. It was established that not all medicines specified in the EML are registered on the territory of Ukraine and included in the Program of Medical Guarantees (PMG).
Conclusion: The PMG includes most of the EML medicines. The modern pharmacotherapy of CHD and comorbid conditions has a positive impact on the budget of the health care system in clinical practice proposed by the ESC/AHA was determined. The lists of medicines in the PMG in Ukraine, need to be revised on the basis of the Health Technology Assessment for further inclusion in the state program 'Affordable Medicines' for long-term use by patients with CHD and comorbid conditions. These measures will improve the quality of pharmaceutical care for these patients.
背景：人口获得药品的问题在世界范围内都具有相关性。正如世界卫生组织和联合国所强调的那样，流行病、自然灾害和战争对人们获得药品产生了负面影响。方法：对乌克兰科学计量数据库（NRAT， OUCI）中的科学出版物进行分析；Scopus、Web of Science、Pubmed、Medline、BMJ和Embase；为冠心病患者及其合并症及其药物成分提供医疗保健的法律领域。比较了欧洲和乌克兰的EML；比较了欧洲/美国心脏病学会（ESC/AHA）和乌克兰对冠心病和合并症患者的临床建议和药物治疗。结果：分析了不属于“负担得起的药物”规划但列入EML清单的药物的价格；确定了在战时条件下乌克兰病人的可用性。为冠心病患者及合并症患者提供医疗服务的法律领域已经形成。经确认，并非《药品清单》规定的所有药品都在乌克兰境内注册并列入《医疗保障方案》。结论：PMG中包含大部分EML药物。ESC/AHA确定了冠心病及合并症的现代药物治疗对临床实践中卫生保健系统预算的积极影响。乌克兰PMG的药物清单需要在卫生技术评估的基础上进行修订，以便进一步纳入国家“负担得起的药物”方案，供冠心病和合并症患者长期使用。这些措施将提高这些患者的药学服务质量。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
